Drug profile · INN
ravulizumab
ULTOMIRIS
ravulizumab (ULTOMIRIS) is a complement c5 inhibitor. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04AA43
Patents linked 0
Pipeline programs 13
News articles 0
Drug details — ravulizumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 13
- Data quality
- 0.83
Quick answer
ravulizumab (ULTOMIRIS) is a complement c5 inhibitor. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN ravulizumab
Brand ULTOMIRIS
Mechanism Complement C5 inhibitor
Target Complement C5
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AA43
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ravulizumab?
ravulizumab (ULTOMIRIS) is a complement c5 inhibitor. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for ravulizumab?
ULTOMIRIS is a marketed brand name for ravulizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.